News

Oculinea, Inc. Enters into Research Agreement with Trican Biotechnology Pipeline

Oculinea, Inc. and Trican Biotechnology based in San Francisco, Ca, and New Taipei City, Taiwan on July 1st, 2025 jointly announced a research collaboration and exclusive option and license agreement to develop a novel ophthalmology implant using antibodies from Trican.  

Landmark UCSF Study Demonstrates Functional Rescue of SCN2A Loss of Function, Underscoring the Potential of Regel Therapeutics' Targeted EpiEditing Platform

The laboratories of Dr. Kevin Bender and Dr. Nadav Ahituv at the University of California, San Francisco, today announced the publication of preclinical proof-of-concept data demonstrating that CRISPR activation restores SCN2A expression and ameliorates disease-related phenotypes in mouse and human...

Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases

Enlaza Therapeutics, the first covalent biologics platform company, today announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals (“Vertex”) (Nasdaq: VRTX) to utilize Enlaza’s proprietary War-Lock™ technology platform to develop small-format drug conjugates and T-cell...

Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia

The US Food and Drug Administration (FDA) has approved Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The approval was based on the pivotal LUNA 3 phase 3 study, in which Wayrilz met the...

Venova Medical Receives FDA IDE Approval for the VENOS-3 Pivotal Study of the Velocity™ Percutaneous AVF System

Venova Medical, a privately held company developing a next-generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access, today announced approval from the US Food and Drug Administration (FDA) to initiate its Multicenter Pivotal Study of the Velocity...

Rezo Therapeutics Appoints Derek Hicks as CEO

Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, today announced that Derek Hicks was appointed CEO. With more than 25 years of leadership in the pharmaceutical and biotech sectors, Derek brings a strong track record of...

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced the closing of its previously announced business combination with Helix Acquisition Corp. II (formerly Nasdaq: HLXB) (“Helix”), a special...

Tahoe Therapeutics Raises $30M to Build World’s Largest Dataset for Training AI Models of Human Cell

Tahoe Therapeutics today announced $30 million in new funding to build the definitive foundational dataset for training Virtual Cell Models. With this, the team will generate one billion single-cell datapoints, mapping one million drug-patient interactions, a scale previously impossible. The...

Do These Two Cancer Drugs Have What It Takes to Beat Alzheimer’s?

Scientists at UC San Francisco and Gladstone Institutes have identified cancer drugs that promise to reverse the changes that occur in the brain during Alzheimer’s, potentially slowing or even reversing its symptoms. More

Dr. Nicole Jiam, Director of the UCSF Otolaryngology Innovation Center, receives a $1.25M National Science Foundation SBIR Phase II award.

UCSF Innovation Ventures congratulates Dr. Nicole Jiam, Director of the UCSF Otolaryngology Innovation Center, and the Co-Founder/CEO of IIAM Health, a healthtech venture, on receiving a $1.25M National Science Foundation SBIR Phase II award. Together with Dr. David Conrad, Dr. Jiam received...